Wedbush Analysts Reduce Earnings Estimates for Sangamo Therapeutics Inc (SGMO)

Sangamo Therapeutics Inc (NASDAQ:SGMO) – Equities researchers at Wedbush cut their Q1 2019 earnings per share (EPS) estimates for Sangamo Therapeutics in a research note issued to investors on Monday, March 11th. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.10). Wedbush has a “Hold” rating and a $10.00 price target on the stock. Wedbush also issued estimates for Sangamo Therapeutics’ Q2 2019 earnings at ($0.16) EPS, Q3 2019 earnings at ($0.17) EPS, FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($1.16) EPS, FY2021 earnings at ($1.40) EPS, FY2022 earnings at ($1.46) EPS and FY2023 earnings at ($1.52) EPS.

SGMO has been the subject of a number of other reports. ValuEngine cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. BidaskClub cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 25th. Finally, Zacks Investment Research cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Sangamo Therapeutics presently has a consensus rating of “Hold” and an average price target of $16.40.

SGMO stock opened at $9.74 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.23 and a quick ratio of 5.23. Sangamo Therapeutics has a one year low of $6.26 and a one year high of $24.70. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -13.91 and a beta of 2.83.

In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Monday, January 7th. The shares were sold at an average price of $12.33, for a total transaction of $61,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 20,000 shares of company stock valued at $224,050. Company insiders own 1.20% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in SGMO. Macquarie Group Ltd. lifted its holdings in shares of Sangamo Therapeutics by 2.7% during the fourth quarter. Macquarie Group Ltd. now owns 53,852 shares of the biopharmaceutical company’s stock worth $618,000 after buying an additional 1,400 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Sangamo Therapeutics by 9.3% during the fourth quarter. Legal & General Group Plc now owns 18,066 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 1,534 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Sangamo Therapeutics by 29.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,552 shares in the last quarter. Vanguard Capital Wealth Advisors lifted its holdings in shares of Sangamo Therapeutics by 11.0% during the fourth quarter. Vanguard Capital Wealth Advisors now owns 21,150 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 2,100 shares in the last quarter. Finally, ClariVest Asset Management LLC lifted its holdings in shares of Sangamo Therapeutics by 2.2% during the fourth quarter. ClariVest Asset Management LLC now owns 118,834 shares of the biopharmaceutical company’s stock worth $1,363,000 after buying an additional 2,586 shares in the last quarter. 62.62% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Story: Net Asset Value

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.